Michael A. Nalesnik, MD
Professor of Pathology
Dr. Nalesnik is a member of the Division of Transplantation Pathology.
Division of Transplantation Pathology
Department of Pathology
UPMC Montefiore, Room E-738
3459 5th Avenue
Pittsburgh, PA 15213
Office Telephone: 412-647-2094
- MD - UMDNJ Rutgers Medical School, 1977
Clinical ExpertiseDr. Nalesnik has over 30 years of experience in transplantation pathology covering all organs and remains an active service pathologist. He has made contributions in the area of posttransplant lymphoproliferative disorders and recently headed a UNOS-based initiative to establish a systematic manner of dealing with the problem of transmission risk of organ donor-associated malignancy.
Research ExpertiseDr. Nalesnik is currently active in the area of hepatocellular carcinoma and provides ongoing support for studies related to donor organ preservation. He played an early role in defining our understanding of the range of lymphoid hyperplasias and neoplasias known collectively as posttransplant lymphoproliferative disorders.
Selected PublicationsView Dr. Nalesnik's publications on PubMed
Nalesnik MA and Michalopoulos GM: Growth Factors and Hepatocellular Carcinoma. An update. Front Biosci (in press 2012).
Nalesnik MA, Tseng G, Ding Y, Xiang GS, Zheng ZL, Yu Y, Marsh JW, Michalopoulos GK, Luo JH: Gene deletions and amplifications in human hepatocellular carcinomas: Correlation with hepatocyte growth regulation. Am J Pathol Feb 8 Epub ahead of print 2012. PMID: 22326833.
Ison MG, Nalesnik MA: An update on donor-derived disease transmission in organ transplantation. Am J Transplant. 2011 Jun;11(6):1123-30. doi: 10.1111/j.1600-6143.2011.03493.x. Epub 2011 Mar 28. PMID: 21443676.
Nalesnik MA, Woodle ES, DiMaio JM, Vasudev B, Teperman LW, Covington S, Taranto S, Gockerman J, Shapiro R, Sharma V, Swinnen L, Yoshida A, Ison MG: Donor transmitted malignancies in organ transplantation: Assessment of clinical risk. Report of the ad hoc Donor Malignancy Subcommittee of the OPTN/UNOS Disease Transmission Advisory Committee (DTAC). Am J Transplant. 2011 Jun;11(6):1140-1147. doi: 10.1111/j.1600-6143.2011.03565.x. PMID: 21645251.
Pomfret EA, Washburn K, Nalesnik M, Douglas D, Wald C, Russo M, Roberts J, Reich D, Mieles L, Lee F, Florman S, Yao F, Harper A, Edwards E, Freeman R, Lake J: Report of a National Conference on Liver Allocation in patients with hepatocellular carcinoma. Liv Transplant 16(3): 262-278, 2010.
Abu-Elmagd KM, Mazariegos G, Costa G, Soltys K, Bond G, Sindhi R, Green M, Jaffe R, Wu T, Koritsky D, Matarese L, Schuster B, Martin L, Dvorchik I, Nalesnik M: Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: Improved outcome with new outlooks. Transplantation Oct 15;88(7):926-34, 2009.
Borhani AA, Hosseinzadeh K, Almusa O, Furlan A, Nalesnik M: Imaging of posttransplantation lymphoproliferative disorder after solid organ transplantation. Radiographics. Jul-Aug;29(4):981-1000; discussion 1000-2, 2009. PMID: 19605652.
Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernandez-Figueras MT, Tolstov Y, Gjoerup O, Mansukhani MM, Swerdlow SH, Chaudhary PM, Kirkwood JM, Nalesnik MA, Kant JA, Weiss LM, Chang Y, Moore PS: Human Merkel cell polyomavirus infection I: MCV T antign expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer. Sep 15;125(6):1243-9, 2009. PMID: 19499546.
Nakao A, Faleo G, Nalesnik MA, Seda-Neto J, Kohmoto J, Murase N: Low dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function. Am J Physiol Renal Physiol. Jul;297(1):F19-26, 2009. PMID: 19369289
Ison MG, Hager J, Blumberg E, Burdick J, Carney K, Cutler J, DiMaio JM, Hasz R, Kuehnert MJ, Ortiz-Rios E, Teperman L, Nalesnik M: Donor-derived disease transmission events in the United States: Data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant. Aug;9(8):1929-35v , 2009.
Nalesnik MA, Federle M, Burk D, Fontes P, Carr BI: Hepatobiliary Effects of 90Yttrium Microsphere Therapy for Unresectable Hepatocellular Carcinoma, Hum Pathol Jan;40 (1): 125-134, 2009.
Dabbs DJ, Ruggiero F, Geisinger KR, Raab SS, Nalesnik M, Silverman JF: Recommendations for the reporting of tissues removed as part of the surgical treatment of malignant liver tumors. Hum Pathol. Nov;35(11):1315-23, 2004.
Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner RH, Swinnen LJ, Woodle ES, Bromberg JS: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68:1517-1525, 1999.
Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE: Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 63(9): 1200-1205, 1997.
Lee ES, Locker J, Nalesnik M, Reyes J, Jaffe R, Alashari M, Nour B, Tzakis A, Dickman PS: The association of Epstein Barr Virus with smooth muscle tumors occurring after organ transplantation. N Engl J Med 332:19 25, 1995.
Locker J and Nalesnik M: Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 135(6):977 987, 1989.
Cleary ML, Nalesnik MA, Shearer WT and Sklar J: Clonal analysis of transplant associated lymphoproliferations based on the structure of the genomic termini of the Epstein Barr virus. Blood 72(1):349 352, 1988.
Nalesnik MA, Jaffe R, Porter KA, Stieber A, Makowka L, Ho M, Atchison RW, Lee RE and Starzl TE: The pathology of post transplant lymphoproliferative disorders occurring in the setting of Cyclosporine A Prednisone immunosuppression. Am J Pathol 133(1):173 192, 1988.
Starzl TE, Iwatsuki S, Shaw BW, Nalesnik MA, Farhi DC, Van Thiel DT: Treatment of fibrolamellar hepatoma with partial hepatectomy or with total hepatectomy and liver transplantation. Surg Gynecol Obstet , 1985.
Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchison RW, Jaffe R, Bahnson HT: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine steroid therapy. Lancet 1:583 587, 1984.